State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.
Overview
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad-sector exposure with a lower cost, while VanEck Biotech ETF (NASDAQ:BBH) provides targeted, concentrated access to biotechnology leaders.
Both funds serve as foundational tools for capturing growth in the medical space, but operate with different levels of specificity. The State Street Health Care Select Sector SPDR ETF represents the broad healthcare landscape within the S&P 500, while the VanEck Biotech ETF targets companies specializing in genetic research and diagnostic technologies.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of trading on July 30.
Source
Originally published at www.fool.com.
Related Articles
- How parents can keep saving for retirement during the expensive childcare years
- Changing how Medicare pays for hospice care could save the U.S. $7.6 billion a year — but at what cost to patients?
- Taxes are on the ballot this fall as Republicans and Democrats grow further apart on whether to raise them